Sanofi Announces €1 Billion Share Buyback Amid Strong Financial Performance
Sanofi has unveiled a €1 billion share repurchase program set to run from February 2026 through December 2026, signaling confidence in its financial trajectory. The MOVE follows a robust fourth quarter where operating profit surged 12.7% to €2.34 billion, with revenues of €11.3 billion exceeding analyst forecasts.
The pharmaceutical giant's immunology and vaccine divisions continue to drive growth, with blockbuster drug Dupixent accounting for nearly 30% of total sales. Gross margins remain healthy at 71.32%, while operating margins reached 21.82% in the latest quarter.
This buyback comes on the heels of a more substantial €5 billion repurchase program in 2025, which included a strategic €3 billion off-market transaction with L'Oréal. Market observers view the continued capital return policy as evidence of Sanofi's strong cash generation capabilities.
